prof. dr. Philippe Gevaert
- ORCID iD
- 0000-0002-1629-8468
Show
Sort by
-
- Journal Article
- A2
- open access
EUFOREA summit in Brussels 2023 : inspiring the future of allergy & respiratory care
-
- Journal Article
- A2
- open access
Chronic rhinosinusitis : matching the extent of surgery with pathology or does the extent of surgery matter?
-
- Journal Article
- A1
- open access
The unified airway hypothesis : evidence from specific intervention with anti–IL-5 biologic therapy
-
The multi-omics single-cell landscape of sinus mucosa in uncontrolled severe chronic rhinosinusitis with nasal polyps
-
- Journal Article
- A1
- open access
The indispensable nasal decongestant : patients' views and perspectives on nasal decongestant overuse
-
- Journal Article
- A2
- open access
Proposal for structured histopathology of nasal secretions for endotyping chronic rhinosinusitis : an exploratory study
-
- Journal Article
- A1
- open access
Respiratory infections and anti-infective medication use from phase 3 dupilumab respiratory studies
-
- Journal Article
- A1
- open access
The roles of eosinophils and interleukin‐5 in the pathophysiology of chronic rhinosinusitis with nasal polyps
-
Reboot surgery for chronic rhinosinusitis with nasal polyposis : recurrence and smell kinetics
-
- Journal Article
- A1
- open access
The role of IgE in upper and lower airway disease : more than just allergy!
-
- Journal Article
- A1
- open access
Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study
-
Phase 3b randomized controlled trial of fevipiprant in patients with nasal polyposis with asthma (THUNDER)
-
- Journal Article
- A1
- open access
Olfactory outcomes with dupilumab in chronic rhinosinusitis with nasal polyps
-
Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps : a randomized, placebo-controlled trial
-
COVID‐19 vaccination with BNT162b2 and ChAdOx1 vaccines has the potential to induce nasal neutralizing antibodies
-
- Journal Article
- A1
- open access
Novel antibody cocktail targeting Bet v 1 rapidly and sustainably treats birch allergy symptoms in a Phase 1 study
-
- Journal Article
- A2
- open access
Pathophysiological and clinical aspects of chronic rhinosinusitis : current concepts
-
Dupilumab provides early and durable improvement of symptoms in patients with chronic rhinosinusitis with nasal polyps : results from the SINUS-24 and SINUS-52 phase 3 trials
(2021) AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE. In American Journal of Respiratory and Critical Care Medicine 203(9S). p.A1341-A1341 -
- Journal Article
- A1
- open access
Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma
-
- Journal Article
- A1
- open access
Indirect treatment comparison of biologics in chronic rhinosinusitis with nasal polyps
-
- Journal Article
- A1
- open access
Dupilumab reduces systemic corticosteroid use and sinonasal surgery rate in CRSwNP
-
Mepolizumab for chronic rhinosinusitis with nasal polyps
-
Mepolizumab improves health related quality of life for patients with chronic rhinosinusitis with nasal polyps : data from the SYNAPSE study
-
Management of patients with chronic rhinosinusitis during the COVID-19 pandemic : an EAACI position paper
-
A 300 IR sublingual tablet is an effective, safe treatment for house dust mite induced allergic rhinitis : an international, double-blind, placebo-controlled, randomized phase III clinical trial
-
Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps : a systematic review for the EAACI guidelines
-
EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics : definitions and management
-
Surgery in nasal polyp patients : outcome after a minimum observation of 10 years
-
Omalizumab or dupilumab for chronic rhinosinusitis with nasal polyposis Reply
-
ARIA digital anamorphosis : digital transformation of health and care in airway diseases from research to practice
-
Personalized medicine for allergy treatment : allergen immunotherapy still a unique and unmatched model
-
Benefits and harm of systemic steroids for short- and long-term use in rhinitis and rhinosinusitis : an EAACI position paper (vol 10, 1, 2020)
-
The role of mobile health technologies in allergy care : an EAACI position paper
-
- Journal Article
- A1
- open access
COVID-19 and olfactory dysfunction : an ENT perspective to the current COVID-19 pandemic
-
- Conference Paper
- C3
- open access
Baseline characteristics of patients with chronic rhinosinusitis with nasal polyps and comorbid asthma from the pooled populations of the SINUS-24 and SINUS-52 Dupilumab phase 3 trials
-
Omalizumab improves outcomes in patients with chronic rhinosinusitis with nasal polyps irrespective of asthma status
(2020) JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. In Journal of Allergy and Clinical Immunology 145(2). p.AB149-AB149 -
Omalizumab improves quality of life in patients with chronic rhinosinusitis with nasal polyps and comorbid asthma
(2020) JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. In Journal of Allergy and Clinical Immunology 145(2). p.AB250-AB250 -
Omalizumab responders analysis in nasal polyposis : a supplementary analysis of the co-primary endpoints of POLYP 1 and POLYP 2 trials
-
Relief of ocular symptoms in patients with house dust mite allergic rhinitis treated with the 300IR house dust mite SLIT tablet
-
The impact of nasal disorders on sleep
-
Omalizumab is associated with a reduced need for surgery in patients with nasal polyposis
-
Dupilumab is associated with lower rates of respiratory infections in patients with chronic rhinosinusitis with nasal polyps-Safety analysis from the SINUS-52 phase 3 trial
-
Using virtual reality during immunotherapy in children : pilot study
-
Reduction in rescue medication use in patients treated with the 300IR house dust mite SLIT tablet
-
The importance of education on nasal spray and eye drop technique: Results from two community-pharmacy based studies
-
Anti-Bet v_1 MAB cocktail reduced birch allergic symptoms within one week, sustained over two months
(2020) ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY. In Annals of Allergy Asthma & Immunology 125(5). p.S19-S19 -
Anti-Bet v_1 MABs reduced basophil responsiveness to birch pollen stimulation ex-vivo in birch allergic patients
(2020) ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY. In Annals of Allergy Asthma & Immunology 125(5). p.S19-S19 -
Indirect treatment comparison of biologics used for the treatment of chronic rhinosinusitis with nasal polyps
(2020) ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY. In Annals of Allergy Asthma & Immunology 125(5). p.S48-S49 -
Continued safety / efficacy of omalizumab in chronic rhinosinusitis with nasal polyps : an open-label extension study
(2020) ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY. In Annals of Allergy Asthma & Immunology 125(5). p.S15-S15 -
- Journal Article
- A1
- open access
Monoclonal antibodies and airway diseases
-
- Journal Article
- A1
- open access
Real-life assessment of chronic rhinosinusitis patients using mobile technology : the mySinusitisCoach project by EUFOREA
-
Clinical research needs for the management of chronic rhinosinusitis with nasal polyps in the new era of biologics : a National Institute of Allergy and Infectious Diseases workshop
-
- Journal Article
- A1
- open access
Allergic respiratory disease care in the COVID-19 era : a EUFOREA statement
-
- Journal Article
- A1
- open access
Efficacy and safety of omalizumab in nasal polyposis : 2 randomized phase 3 trials
-
- Journal Article
- A1
- open access
Molecular profiling of allergen-specific antibody responses may enhance success of specific immunotherapy
-
- Conference Paper
- C3
- open access
Using virtual reality during immunotherapy for children : pilot study
-
European position paper on rhinosinusitis and nasal polyps 2020
-
- Journal Article
- A1
- open access
Benefits and harm of systemic steroids for short- and long-term use in rhinitis and rhinosinusitis : an EAACI position paper
-
Dupilumab reduces opacification across all sinuses and related symptoms in patients with CRSwNP
-
Dupilumab improves health‐related quality of life in patients with chronic rhinosinusitis with nasal polyposis
-
A novel double-blind, placebo-controlled food challenge matrix for milk and raw egg
-
Rhinitis medication use in patients with persistent rhinitis: Belgian cross-sectional study with historical control
-
Efficacy of a 300IR house dust mite tablet is consistent when evaluated by the proportion of symptom-controlled days: Results of a large randomised, double-blind placebo-controlled, multicentre trial
-
Quality of life in patients with house dust mite-associated allergic rhinitis treated with 300IR house dust mite sublingual tablet : results of a large multicentre clinical trial
-
Efficacy and safety of the 300 IR sublingual tablet for the treatment of house dust mite-associated allergic rhinitis : a multicentre, international, dbpc, randomized phase III clinical trial
-
Mite immunotherapy with Alutard SQ 510 induces an incomplete protective antibody response
-
Severe asthma : entering an era of new concepts and emerging therapies : highlights of the 4th International Severe Asthma Forum, Madrid, 2018
-
Prioritizing research challenges and funding for allergy and asthma and the need for translational research : the European Strategic Forum on Allergic Diseases
-
Severe spontaneous epistaxis : retrospective study in a tertiary ENT centre
-
Much ado about biologicals : highlights of the Master Class on Biologicals, Prague, 2018
-
'Blockers' can benefit from 300IR house dust mite tablet-results of a large multicentre clinical trial in house dust mite induced allergic rhinitis patients
-
A prospective, feasibility study to evaluate the efficacy and usability of a novel drivable endoscope in patients with chronic rhinosinusitis
-
Omalizumab efficacy and safety in nasal polyposis : results from two parallel, double-blind, placebo-controlled trials
(2019) ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY. In Annals of Allergy Asthma & Immunology 123(5). p.S17-S17 -
Dupilumab improves patient-reported outcomes in chronic Rhinosinusitis with nasal polyps and comorbid asthma : sinus-24/sinus-52 trials
-
ARIA masterclass 2018 : from guidelines to real-life implementation
-
Baseline characteristics of phase 3 randomized controlled trials of omalizumab in chronic rhinosinusitis with nasal polyps
-
Real-life assessment of chronic rhinosinusitis patients using mobile technology
-
Immundefekte bei chronischer Rhinosinusitis : eine bedeutende und oft unterschätzte Ursache
-
EPOS2020 : development strategy and goals for the latest European Position Paper on Rhinosinusitis
-
- Journal Article
- A1
- open access
Twelve-year follow-up study after endoscopic sinus surgery in patients with chronic rhinosinusitis with nasal polyposis
-
Endoscopic sinus surgery for type‐2 CRS wNP : an endotype‐based retrospective study
-
- Journal Article
- A1
- open access
Stepwise approach towards adoption of allergen immunotherapy for allergic rhinitis and asthma patients in daily practice in Belgium : a BelSACI-Abeforcal-EUFOREA statement
-
mySinusitisCoach : patient empowerment in chronic rhinosinusitis using mobile technology
-
Subtypisierung der Polyposis nasi : Phänotypen, Endotypen und Komorbiditäten
-
Atopic comorbidities and biomarkers of type 2 inflammation in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP) who failed intranasal corticosteroids
-
Emerging roles of innate lymphoid cells in inflammatory diseases : clinical implications
-
- Journal Article
- A1
- open access
Intranasal administration of allergen increases specific IgE whereas intranasal omalizumab does not increase serum IgE levels : a pilot study
-
EAACI position paper on the standardization of nasal allergen challenges
-
- Journal Article
- A1
- open access
Safety and efficacy of immunotherapy with the recombinant B-cell epitope-based grass pollen vaccine BM32
-
FcεRI expression and IgE binding by dendritic cells and basophils in allergic rhinitis and upon allergen immunotherapy
-
- Miscellaneous
- open access
What treatments are effective for common cold in adults and children?
-
- Journal Article
- A1
- open access
Development and validation of a standardized double-blind, placebo-controlled food challenge matrix for raw hazelnuts
-
Implementation of latex allergy clinical care pathways
-
Prospective study on the outcome of the sphenoid drill out procedure
-
- Conference Paper
- C3
- open access
Extent of sinus involvement in patients with bilateral nasal polyposis (NP) : baseline sinus ct scan results from a phase 2a study
-
Suppression of allergen-induced basophil activation upon treatment with subcutaneous house dust mite immunotherapy: a prospective study
-
Probiotics-impregnated bedding covers in house dust mite allergic rhinitis patients : a double-blind, randomised, placebo-controlled, crossover clinical trial
-
Dupilumab improves sense of smell and reduces anosmia among patients with nasal polyposis and chronic sinusitis : results from a phase 2a trial
-
A possible role of stem cells in nasal polyposis
-
The effect of systemic treatments on periostin expression reflects their interference with the eosinophilic inflammation in chronic rhinosinusitis with nasal polyps